Literature DB >> 21154820

MicroRNAs and other small silencing RNAs in cancer.

Carlos Rovira1, Maria C Güida, Alfonso Cayota.   

Abstract

Small noncoding RNAs are key controllers of cellular function, and their deregulation can lead to cancer development and metastatic evolution. This review summarizes the most important examples of small RNAs involved in human cancer and discusses their clinical use as biomarkers and drug targets for diagnosis, prognosis, and treatment of cancer. We also describe the possible mechanisms underlying small RNA-mediated transformation and outline the future describing new small RNA families with great potential in cancer biology.
© 2010 IUBMB.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21154820     DOI： 10.1002/iub.399

Source DB:  PubMed          Journal:  IUBMB Life        ISSN： 1521-6543            Impact factor:   3.885


  9 in total

1.  MicroRNA-340 as a modulator of RAS-RAF-MAPK signaling in melanoma.

Authors:  Ashley M Poenitzsch Strong; Vijayasaradhi Setaluri; Vladimir S Spiegelman
Journal:  Arch Biochem Biophys       Date:  2014-07-17       Impact factor: 4.013

2.  rna interference targeting p110β reduces tumor necrosis factor-alpha production in cellular response to wear particles in vitro and osteolysis in vivo.

Authors:  Jian-bin Huang; Yue Ding; Dong-sheng Huang; Wei-ke Zeng; Zhi-ping Guan; Mao-lin Zhang
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

3.  MicroRNAs activate natural killer cells through Toll-like receptor signaling.

Authors:  Shun He; Jianhong Chu; Lai-Chu Wu; Hsiaoyin Mao; Yong Peng; Christopher A Alvarez-Breckenridge; Tiffany Hughes; Min Wei; Jianying Zhang; Shunzong Yuan; Sumeet Sandhu; Sumithira Vasu; Don M Benson; Craig C Hofmeister; Xiaoming He; Kalpana Ghoshal; Steven M Devine; Michael A Caligiuri; Jianhua Yu
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

4.  Global dysregulation of the chromosome 14q32 imprinted region in uterine carcinosarcoma.

Authors:  Eric J Devor; Jillian N DE Mik; Shyam Ramachandran; Michael J Goodheart; Kimberly K Leslie
Journal:  Exp Ther Med       Date:  2012-01-25       Impact factor: 2.447

5.  Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia.

Authors:  Hun Ju Lee; Josephia R Muindi; Wei Tan; Qiang Hu; Dan Wang; Song Liu; Gregory E Wilding; Laurie A Ford; Sheila N J Sait; Annemarie W Block; Araba A Adjei; Maurice Barcos; Elizabeth A Griffiths; James E Thompson; Eunice S Wang; Candace S Johnson; Donald L Trump; Meir Wetzler
Journal:  Cancer       Date:  2013-10-25       Impact factor: 6.860

6.  Inhibition of mesothelin as a novel strategy for targeting cancer cells.

Authors:  Kun Wang; Vidya Bodempudi; Zhengian Liu; Emma Borrego-Diaz; Farnaz Yamoutpoor; Anna Meyer; Richard A Woo; Weihong Pan; Arkadiusz Z Dudek; Mojtaba S Olyaee; Tuba Esfandyari; Faris Farassati
Journal:  PLoS One       Date:  2012-04-02       Impact factor: 3.240

7.  The micro RNA hsa-miR-377-3p inhibits tumor growth in malignant melanoma.

Authors:  Jian Yuan; Lei Jiang; Chaotang Guo
Journal:  RSC Adv       Date:  2019-06-17       Impact factor: 3.361

8.  Skin sensitizers differentially regulate signaling pathways in MUTZ-3 cells in relation to their individual potency.

Authors:  Ann-Sofie Albrekt; Henrik Johansson; Anna Börje; Carl Borrebaeck; Malin Lindstedt
Journal:  BMC Pharmacol Toxicol       Date:  2014-02-11       Impact factor: 2.483

9.  MicroRNA miR-188-5p as a mediator of long non-coding RNA MALAT1 regulates cell proliferation and apoptosis in multiple myeloma.

Authors:  Hui Liu; Zuofei Chi; Hong Jin; Wei Yang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.